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alternative ﬂow-diverting strategy in the
management of peripheral and visceral aneurysms
Yongxue Zhang, MD,a,b Qingsheng Lu, MD,a Zhiqing Zhao, MD,a Junmin Bao, MD,a Xiang Feng, MD,a
Rui Feng, MD,a and Zaiping Jing, MD,b Shanghai, China
Objective: In this study we aimed to report on the midterm outcome of multiple overlapping uncovered stents in the
treatment of peripheral and visceral aneurysms, and analyze the possible factors affecting the treatment efﬁcacy.
Methods: Data of patients who were regularly followed up over 24 months were retrospectively reviewed. Descriptive
statistics were applied to present aneurysm thrombosis process and diameter change at each follow-up point, and a
comparison with the baseline level was performed. Patients were divided into a totally thrombosed (TT) group and a
residual perfusion (RP) group according to the sac thrombosis ratio (thrombus volume to sac volume ratio) at 3, 6, and
12 months of follow-up. Aneurysm shrinkage in the two groups was compared to explore the effect of the initial RP on
the treatment outcome. Patients were also grouped based on their aneurysm morphology (saccular/fusiform). The
aneurysm sac thrombosis speed (time to thrombosis) and diameter decrease (DD) ratio (percentage of DD) were
compared between the two groups to understand the inﬂuence of aneurysm shape on the treatment efﬁcacy.
Results: Of the 64 patients treated, the initial 37 patients (25 male; average age, 55.5 6 13.0 years) were enrolled
into this study. Technical success rate was 100%. All patients were regularly followed up. At 24 months, 94.6%
aneurysms (35/37) were TT, and the maximum aneurysm diameter decreased from 36.5 6 9.7 mm preoperatively
to 23.6 6 7.7 mm (P < .001). Overall clinical success rate (complete thrombosis and shrinkage/stabilization of the
aneurysm without aneurysm-related mortality) reached 94.6% in the study cohort. Most side branches (31/33)
covered by the bare stent stayed patent during follow-up. Initial sac RP at 3, 6, and 12 months might not fully affect
the ﬁnal aneurysm DD ratio (TT group: 0.37 6 0.09, 0.35 6 0.09, and 0.35 6 0.09; compared with the RP group:
0.33 6 0.09, 0.36 6 0.11, and 0.36 6 0.13; P [ .153, .964, and .418, respectively). At 3 and 6 months follow-up,
saccular aneurysms (n [ 29) seemed to have a faster thrombosis speed compared with fusiform aneurysms (78.1 6
26.8% and 83.9 6 21.8% vs 47.0 6 24.4% and 63.9 6 22.6%; P [ .004 and .013, respectively), but there was no
signiﬁcant difference in aneurysm shrinkage ratio at 24 months between the two groups (0.36 6 0.10 vs 0.33 6
0.06; P [ .357).
Conclusions:Multiple overlapping uncovered stents could be a feasible option for the endovascular treatment of peripheral
and visceral aneurysms. Neither the aneurysm shape nor the initial sac RP would affect the midterm treatment outcome.
Further validation of this technique is required to substantiate these results. (J Vasc Surg 2014;60:1209-17.)Although rare, peripheral (PAAs) and visceral artery
aneurysms (VAAs) can be life-threatening because of their
potential risk of rupture and distal embolism to target or-
gans.1 When ruptured, which occurs in approximately
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://dx.doi.org/10.1016/j.jvs.2014.04.074mortality rate of up to 70%.2 Although open surgical repair
is traditionally considered as the gold standard for the treat-
ment, endovascular techniques have become a valid alter-
native in recent decades and are gaining more and more
acceptance, especially in the management of high surgical
risk patients.3
A new concept of ﬂow-diverting uncovered stent
emerged in 2008.4 Unlike traditional stent grafts, it has
been designed to slow and laminate blood ﬂow inside the
aneurysm, encouraging the formation of an organized
thrombus within the sac, and thus theoretically minimizing
the chances of aneurysm rupture.5 Meanwhile, because of
the porous nature of the uncovered stents, the side
branches within the stenting zone could be preserved,
which could minimize the risk of target organ ischemia.
The commercially available Cardiatis multilayer stent
(CMS; Cardiatis, Isnes, Belgium) has been applied in the
treatment of PAAs and VAAs since 2008, and the treat-
ment outcome seems encouraging so far.4,6-8
Modern computational studies have demonstrated that
the mesh porosity of the stents might play an important
role in the ﬂow-modulating effect.9 Optimal hemodynamic1209
Fig 1. Procedure details of using multiple overlapping uncovered stents (MOUSs) to treat peripheral and visceral
aneurysms. A, A left renal artery aneurysm (arrow) was detected using computed tomography (CT) angiography. B-D,
Preoperative angiogram conﬁrmed the size and location of the aneurysm, and the stent diameter was oversized by 1 mm
referring to the aneurysm neck (B).D, A stiff wire was placed bridging the aneurysm (arrow heads), following which the
stentswere advanced anddeployed to cover the aneurysm (arrow), leaving at least 10mm lesion-free proximal and distal to
the landing zone.C, An angiogramwas made after each stent deployment to evaluate the ﬂow velocity change within the
aneurysm sac until it was signiﬁcantly decreased on ﬂuoroscope. E and F, CT angiography at 3-month follow-up (F)
demonstrated complete thrombosis and shrinkage of the aneurysm sac compared with preoperative measurements (E).
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65%.10 To reach such low mesh porosity while maintaining
the ﬂexibility of the stent, we have applied multiple over-
lapping uncovered stents (MOUSs) in our center as an
alternative to the commercial CMS, which is still not avail-
able in China and many other places. Early clinical applica-
tion of MOUSs in PAAs and VAAs has achieved a
satisfactory short-term outcome, with a technical success
rate of 100%.11
The current study aimed at reporting the midterm
outcome of the initial study cohort of patients who under-
went MOUS therapy at 2-year follow-up, and analyzed the
possible factors that might inﬂuence the treatment efﬁcacy.
METHODS
This study was approved by the Institutional Review
Board of Changhai Hospital, and written informed consent
was obtained from each patient before surgery.
Patient enrollment criteria. A retrospective review of
a prospectively maintained database which was set up in
2009 was performed to identify patients who underwent
the MOUS procedure for the treatment of their PAAs or
VAAs. The patient selection criteria were: (1) the patient
was diagnosed with PAAs or VAAs using computed to-
mography (CT) angiography, and there was no sign of
aneurysm rupture, or approaching rupture at admission,
otherwise emergent open surgery would be performed;
(2) the patient was judged to be a poor candidate for
open surgical repair because of comorbidities or age by a
multidisciplinary surgical team, or open surgery was refusedby the patient; (3) the aneurysm was complicated by side
branches, or tortuous target vessels, which precluded the
application of traditional stent grafts; and (4) the patient
was regularly followed up more than 24 months.
The patient demographic characteristics, coexisting
medical conditions, surgical details, and pre- and postoper-
ative CT images were collected for analysis.
Intervention. Selection of the arterial access was based
on the anatomic location of the aneurysms and the evalua-
tion of the level of difﬁculty in target vessel catheterization.
Using local anesthesia, a standard percutaneous puncture
of the access artery was performed and heparin was given
intra-arterially (80 U/kg). An angiogram was performed
to conﬁrm the size and location of the aneurysm, followed
by selective catheterization of the target vessel. A stiff wire
was then placed, bridging the lesion segment, following
which the uncovered stents (OptiMed, Ettlingen,
Germany) were advanced and deployed consecutively to
cover the aneurysm, leaving at least a 10-mm lesion-free
landing zone at its proximal and distal neck (Fig 1). The
diameter of the stents was oversized by 1 mm, which was
recommended in the literature.12 The number of the stents
placed was determined using an intraoperative angiogram
with the criterion that the ﬂow velocity within the aneu-
rysm sac was signiﬁcantly decreased on ﬂuoroscope imag-
ing (Videos 1 and 2, online only). A vascular closure device
(Angio-Seal; St Jude Medical, St Paul, Minn) were used to
manage the access site after intervention.
Technical success was deﬁned as successful deployment
of the stents to target locations without procedure-related
Fig 2. Follow-up imaging and parameters measurement. Computed tomography (CT) angiography was used to follow
up the evolution of the aneurysm. Three-dimensional reconstruction of the aneurysm was conducted with dedicated
CT image processing software (A-C). Aneurysm maximum diameter was measured on the cross-sectional slices
perpendicular to the diseased artery (D-F); the area of sac residual perfusion (RP) was measured on each slice, then put
together to calculate the sac thrombosis ratio (STR) (G-I).
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and perioperative mortality.13,14 All patients were discharged
with dual antiplatelet therapy (aspirin at 100 mg/d and
clopidogrel at 75 mg/d).
CT image analysis. All patients who underwent the
MOUS procedure were regularly followed up initially and
at 3 and 6 months postoperatively, and then every 6 months
afterward. CT angiography examination (Sensation Cardiac
64; Siemens, Munich, Germany) was scheduled at each
follow-up point (Fig 2). The CT data were processed with
Aquarius workstation software (TeraRecon, Foster City,
Calif) for three-dimensional reconstruction of the arterial
contour (Fig 2, A-C). Aneurysm maximum diameter was
measured on the cross-sectional image perpendicular to the
diseased vessel (Fig 2, D-F). Aneurysm maximum diameterdecrease (DD) and diameter decrease ratio (DDR) at each
follow-up point were calculated using the following formula:
DDi ¼ Dpre Di and DDRi ¼

Dpre Di

Dpre
where DDi and DDRi stand for the aneurysm DD and
DDR at imonths follow-up, respectively. Dpre andDi stand
for the aneurysm diameter before surgery and at i months
of follow-up, respectively.
Aneurysm sac thrombosis ratio (STR) was deﬁned as
the total thrombus volume over the whole aneurysm sac
volume, and was calculated according to the following
formula:
STRI ¼
X
ðAthrombus  ST Þ
.X
ðAsac  ST Þ
Table I. Patient demographic and clinical data
Variables Mean 6 SD or No. (%)
Demographic characteristics
Age, years 55.5 6 13.0
Male sex 25 (67.6)
Comorbidities
Hypertension 14 (37.8)
COPD 8 (21.6)
Renal failure 8 (21.6)
Coronary artery disease 7 (18.9)
Aortic pathology 5 (13.5)
Diabetes 5 (13.5)
Stroke 2 (5.4)
Hepatitis 1 (2.7)
Aneurysm locations
Renal artery 8 (21.6)
Superior mesenteric artery 6 (16.2)
Spleen artery 6 (16.2)
Popliteal artery 5 (13.5)
Iliac artery 4 (10.8)
Hepatic artery 3 (8.1)
Left subclavian artery 2 (5.4)
Celiac artery 2 (5.4)
Innominate artery 1 (2.7)
Side branches covered
Internal iliac artery 4 (12.1)
Right gastric artery 2 (6.1)
Gastroduodenal artery 2 (6.1)
Vertebral artery 2 (6.1)
Left gastric artery 2 (6.1)
Splenic artery 2 (6.1)
Other minor branches 19 (57.6)
COPD, Chronic obstructive pulmonary disease; SD, standard deviation.
JOURNAL OF VASCULAR SURGERY
1212 Zhang et al November 2014where STRi stands for the STR at i months of follow-up,
Athrombus and Asac stand for the thrombus area (Fig 2,
H-I) and the whole sac area on the cross-sectional images,
respectively, and ST stands for the slice thickness of the
scan protocol.
Clinical success was deﬁned in terms of complete aneu-
rysm thrombosis, aneurysm shrinkage or stabilization, and
absence of aneurysm-related mortality during follow-up.
Subgroup design. Residual perfusion (RP) of the
aneurysm sac immediately after deployment of the ﬂow-
diverting stents was a commonly observed phenomenon
in our previous pilot study and in the literature.7,11 To
explore the effect of this initial RP at 3, 6, and 12-month
follow-up on the midterm treatment outcome, we
divided the study cohort into two subgroups according to
the sac thrombosis status at each follow-up point: (1)
totally thrombosed (TT) group: patients with a TT aneu-
rysm sac at the observation point; and (2) RP group: pa-
tients with RP of the sac at the observation point
(regardless of whether the RP would stop in the future).
Treatment outcome of the two groups was evaluated using
their ﬁnal aneurysm DD value (DD24m) and DDR value
(DDR24m) at 24 months follow-up.
Hemodynamics in a saccular aneurysm might differ
greatly from that in a fusiform aneurysm.15 To understand
whether the aneurysm morphology could affect the throm-
bosis process and treatment outcome, we also divided thepatients into a saccular-aneurysm group and a fusiform-
aneurysm group, using STRi and DDRi at each follow-up
point as parameters for between-group comparisons.
Statistical analysis. Continuous data are presented as
mean 6 standard deviation, and categorical data are listed
as the counts. The Shapiro-Wilk method was performed to
test the normality of the data before between-group
comparisons were made. Two-tailed Student t-test was
applied to analyze the signiﬁcance of difference if the data
passed the normality test; otherwise the nonparametric
Wilcoxon test was used. Statistical signiﬁcance was assumed
if P < .05. SPSS 13.0 (SPSS Inc, Chicago, Ill) was used for
the statistical analysis.
RESULTS
From November 2009 to February 2014, a total of 64
PAA/VAA patients were treated with the MOUS therapy
in our center. Of them, the initial 37 patients (25 male;
average age, 55.5 6 13.0 years) who had been regularly
followed over 2 years were enrolled into this retrospective
analysis for the midterm outcome. The demographic and
clinical data of these patients are listed in Table I.
General statistics. Technical success was achieved in
all patients. The mean number of stents implanted was
3.2 6 0.4 (three stents in 31 patients and four stents in
six patients). Average procedure time was 86.5 6 23.6
minutes. Average length of hospital stay was 6.8 6 1.6 days.
One patient developed access hematoma, which resolved
before discharge. For the rest of the patients, the postoper-
ative course was uneventful. No patient was lost to follow-
up within the study period.
Aneurysm maximum diameter and STR data before
and after intervention failed the normality test, therefore
the nonparametric Wilcoxon method was applied to deter-
mine their evolution trend during follow-up in the 37 pa-
tients. The average aneurysm maximum diameter at
baseline was 36.5 6 9.7 mm, which decreased to 34.5 6
9.6 mm (P < .001) at the 3-month, 31.7 6 9.4 mm
(P < .001) at the 6-month, 29.1 6 8.6 mm (P < .001)
at the 12-month, 26.3 6 7.4 mm (P < .001) at the 18-
month, and 23.6 6 7.7 mm (P < .001) at the 24-month
follow-ups (Fig 3, A); the mean STR before surgery was
13.6 6 15.4%, which increased to 85.0 6 21.4% at
the 3-month (P < .001), 93.2 6 14.9% at the 6-month
(P < .001), 96.9 6 8.5% at the 12-month (P < .001),
98.4 6 5.0% at the 18-month (P < .001), and 99.1 6 4.1
at the 24-month follow-ups (P < .001) (Fig 3, B). There
was no mortality documented during the follow-up. Clin-
ical success was achieved in all patients except two who
presented with residual sac perfusion at the end of
24 months (94.6%).
Thirty-three side branches in 28 patients were covered
by the bare stents (7 sprouted directly from the aneurysm
wall, 26 were adjacent to the aneurismal lesion), of which
31 stayed patent during follow-up (93.9%). In particular,
in the seven aneurysms with side branches sprouting
directly from the aneurysm wall, the formation of a special
anatomic ﬂow path inside the aneurysm sac was noticed,
Fig 3. Change in aneurysm maximum diameter and sac throm-
bosis ratio (STR) during regular follow-up. A, Statistical signiﬁ-
cance was demonstrated in terms of aneurysm maximal diameter
decrease (DD) (n ¼ 37) and (B) aneurysm thrombosis ratio at
each follow-up point (n ¼ 37) compared with baseline level.
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gradually thrombosed and shrunk (Fig 4). Occlusion of
one branch was seen in two patients, but without clinical
consequences of target organ ischemia. Stent occlusion at
3 months was documented in one patient who failed to
comply with the dual antiplatelet therapy, making an over-
all stent patency rate of 97.3% (36/37).
Subgroup analysis. Initial RP of the aneurysm sac
might not affect the treatment outcome of MOUSs
(Table II). Only 62.2% (23/37) of the aneurysms were
TT at the 3-month follow-up (TT group: 23 patients, RP
group: 14 patients). A comparison of their DD24m and
DDR24m demonstrated that the mean aneurysm shrinkage
was of no signiﬁcant difference between the two groups
(DD24m: 13.176 3.98 mm; DDR24m: 0.376 0.09 for theTT group vs DD24m: 12.36 6 5.95 mm; DDR24m: 0.33 6
0.09 for the RP group; P ¼ .619 and 0.153, respectively);
at the 6-month follow-up, 81.1% (30/37) aneurysms
were completely thrombosed (TT group: 30 patients; RP
group: seven patients), DD24m and DDR24m for each
group were 12.82 6 4.58 mm (0.35 6 0.09) vs 13.07 6
5.82 mm (0.36 6 0.11) (P ¼ .900 and .964, respectively).
By the end of 12 months, 86.5% (32/37) aneurysm sacs
were full of thrombus (TT group: 32 patients; RP group:
ﬁve patients), and no statistical signiﬁcance was found in
terms of aneurysm DD between the two groups (DD24m:
12.64 6 4.50 mm; DDR24m: 0.35 6 0.09 compared with
DD24m: 14.30 6 6.61 mm, DDR24m: 0.36 6 0.13; P ¼
.476 and .418, respectively). Because only four or fewer
patients presented with RP after 18 months, no further
comparison was made between the two subgroups.
Aneurysm morphology could affect the initial aneu-
rysm thrombosis process, but it might not be associated
with aneurysm shrinkage (Fig 5). Of the 37 aneurysms
treated, 29 were saccular, and the remaining eight were
fusiform in shape. A comparison between the two sub-
groups demonstrated that thrombus in saccular aneurysms
tended to grow faster at the 3-month (increase of 78.1 6
26.8%) and 6-month (increase of 83.9 6 21.8%) follow-
ups compared with fusiform aneurysms (STR increased
by 47.0 6 24.4% and 63.9 6 22.6% at 3 and 6 months;
P ¼ .004 and .013, respectively). With longer follow-up
($12 months), the thrombosis speed of the two types of
aneurysm was almost the same. As for the aneurysm
shrinkage process, there was no signiﬁcant difference in
DDRi between the two groups at each follow-up point
(0.06 6 0.05, 0.13 6 0.09, 0.20 6 0.10, 0.28 6 0.09,
and 0.36 6 0.10 for saccular aneurysms vs 0.04 6 0.02,
0.14 6 0.06, 0.21 6 0.07, 0.26 6 0.05, and 0.33 6
0.06 for fusiform aneurysms; P ¼ .171, .750, .934, .580,
and .357, respectively).
DISCUSSION
Several endovascular strategies have been described in
the literature for the management of PAAs/VAAs in
high-risk patients, such as embolization of target vessels,
stent grafting, or stent-assist coiling.16-18 The major tech-
nical difﬁculties of these endovascular approaches have al-
ways been the inability to completely preserve the
collateral vessels,19 which carries a potential risk of ischemic
complication of the end organs.
With the new concept ﬂow-diverting stents, which have
a potential capacity of preserving the collaterals while
excluding the aneurysm, this drawback of the endovascular
technique might be overcome. Unlike a stent graft that
aims at creating a mechanical barrier between the normal
blood ﬂow and the aneurysm sac, the uncovered stent is
designed to slow the ﬂow velocity within the sac, thus
creating a favorable environment for the thrombus deposi-
tion.10 Pooled data regarding the efﬁcacy of this technique
from different centers has demonstrated an overall technical
and clinical success rate of 98.1% and 89.5%, respectively
(Table III).3,7,11,12,20-23 Most frequent complications
Fig 4. Preservation of side branches arising directly from the aneurysm (An) wall. A and B, A left subclavian artery An
involving the left vertebral artery (VA) was treated using 3 layers of bare stents (Sts). C, At 6-month follow-up, an
anatomic path was observed to form inside the An sac, providing blood supply to the VA, and the rest of the sac was
totally thrombosed (TT) and signiﬁcantly shrunken. D and E, Possible hemodynamic mechanism involved in the
formation process of the special anatomic ﬂow path. The blood ﬂow was redirected by the bare Sts toward the side
branch, and thrombus began to grow in the rest of the sac. Ao, Aorta; BA, brachial artery.
Table II. Effect of initial sac perfusion at 3, 6, and 12 postoperative months on the aneurysm diameter change at the end
of 2-year follow-up
Observation
point, months
DD24m
P
DDR24m
P
TT group RP group TT group RP group
No. Mean 6 SD No. Mean 6 SD No. Mean 6 SD No. Mean 6 SD
3 23 13.17 6 3.98 14 12.36 6 5.95 .619 23 0.37 6 0.09 14 0.33 6 0.09 .153
6 30 12.82 6 4.58 7 13.07 6 5.82 .900 30 0.35 6 0.09 7 0.36 6 0.11 .964
12 32 12.64 6 4.50 5 14.30 6 6.61 .476 30 0.35 6 0.09 5 0.36 6 0.13 .418
DD24m, Aneurysm diameter (mm) change at 24-month follow-up; DDR24m, aneurysm diameter change ratio at 24-month follow-up; RP group, group with
residual sac perfusion; SD, standard deviation; TT group, group with totally thrombosed (TT) sac.
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nection (2.8%); reported branch patency rate varied greatly
from 25% to 100%.
The major technical problem of the commercial CMS
seems to be the stent longitudinal shortening during
deployment, which is thought to be a result of the woolen
cobalt design of the stent.24 Difﬁculties in predicting the
shortening extent had led to extra stent deployment in
several cases.25 Using laser-engraved bare metal stents as
we did in our center might avoid such problems. In our
study cohort with 37 patients, stent shortening was not
observed during deployment, leading to a technical success
rate of 100%.Dual antiplatelet therapy is essential to maintain the
patency of the stents. One of our patients with a renal
artery aneurysm presented with stent occlusion at the
3-month follow-up because of his noncompliance of the
antiplatelet medication. Because there were no severe clin-
ical symptoms, and we noticed a collateral circulation
feeding the kidney, the patient was treated conservatively.
Most side branches (31/33) were successfully preserved
during follow-up, and no sign of end-organ ischemia was
documented.
Because of the antiplatelet therapy, the aneurysm sac
thrombosis process could take 12 months or longer and
the initial sac perfusion was commonly observed in patients
Fig 5. Differences in aneurysm evolution during follow-up be-
tween saccular and fusiform aneurysms. Aneurysm sac thrombosis
speed was faster in saccular aneurysms at 3 and 6 months
compared with fusiform aneurysm (A). The difference became less
signiﬁcant over time. B, The maximum diameter decrease (DD)
ratio between the two groups was not signiﬁcant at each follow-up
point.
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study we found that the initial sac perfusion within
12 months might not be associated with the treatment
outcome. A comparison between the TT and RP groups,
which were divided at the 3-, 6-, and 12-month follow-
up points, respectively, demonstrated that there was no sig-
niﬁcant difference in their aneurysm shrinkage degree atthe end of 24 months of follow-up. A similar opinion
was expressed in the literature.26 However, this conclusion
should be drawn with caution, because aneurysm rupture
due to incomplete sac thrombosis has been reported in
the aortic segment.27
Hemodynamic characteristics in a saccular aneurysm
might differ greatly from that in a fusiform aneurysm, but
the MOUS treatment outcome in the two types of aneu-
rysm was similar. Despite the difference in initial sac
thrombus deposition speed at 3 and 6 months, the two
kinds of aneurysm tended to respond similar to the ﬂow-
diverting stents in term of aneurysm DDR at each
follow-up point. This result is in contrast with the study
by Rufﬁno and Rabbia, in which a signiﬁcant difference
in the cumulative shrinkage at 12 months between saccular
and fusiform aneurysms was documented.7 Possible rea-
sons for the discordance might be multifold, but the
main factor is thought to be the stenting strategy: because
the hemodynamics of saccular and fusiform aneurysms dif-
fers greatly, optimal stent mesh porosity to treat the two
types of aneurysms might vary, especially taking into ac-
count the individual differences of the patients. However,
the commercial CMS is designed with ﬁxed mesh porosity,
which is difﬁcult to adjust during surgery. This might lead
to insufﬁcient exclusion of the aneurysms in some cases. In
contrast, we adopted multiple uncovered stents placed in
an overlapping fashion to form a porous stent system.
The number of stents was determined using an intraopera-
tive angiogram to achieve a signiﬁcant decrease in ﬂow ve-
locity on ﬂuoroscopic evaluation in each individual,
therefore the risk of insufﬁcient exclusion of the aneurysm
was minimized.
The exact hemodynamic mechanism of the ﬂow-
diverting stents in preserving side branches remains unex-
plained, especially when the side branch sprouts directly
from the aneurysm wall. Several previous studies have sug-
gested that ﬂow-diverting stents could alter the local ﬂow
pattern and redirect the blood stream into the side
branches,4,28 and that the outﬂow runoff might be the
main factor to maintain side branch patency.14 These the-
ories are in accordance with the present clinical study, in
which a special anatomic ﬂow path was observed to form
inside the aneurysm sac feeding the side branch, and the
rest of the sac gradually thrombosed (Fig 4, D and E).
A hypothesis could be formulated that this ﬂow path might
be surrounded by thrombus at ﬁrst, and then endothelium
might begin to grow along the path to separate it from the
thrombus.
The major limitations of this study were the retrospec-
tive nature of the analysis and relatively small patient
cohort. Therefore, the conclusions drawn from the result
should not be considered robust. Further prospective clin-
ical studies should be performed to overcome these
limitations.
CONCLUSIONS
Endovascular management of PAAs/VAAs using the
MOUS therapy could be a feasible alternative in patients
Table III. Reported series of ﬂow-diverting stents in the management of peripheral/visceral aneurysm
No. Center Year
Volume
(Pat/An), No.
Follow-up,
months
Technical
success, %
Clinical
success, % Complication
Branch
patency, %
All-cause
mortality
1 Ferrero et al20 2011 2 (4) 12 100 75 Stent D (n ¼ 1) 100 0
2 Ferrero et al3 2011 4 (4) 12.4 75 75 Stent S/O (n ¼ 1) d 1
3 Rufﬁno and Rabbia7 2012 54 (54) 12 98.1 93.3 Stent S/O (n ¼ 6)
Stent D (n ¼ 2)
96.1 3
4 Antoniou et al21 2012 3 (6) 9 100 66.7 Stent S/O (n ¼ 2) d 0
5 Zhang et al11 2012 24 (24) 18 100 100 d 100 0
6 Balderi et al12 2013 5 (5) 31.2 100 80 Stent S/O (n ¼ 2) 100 0
7 Reijnen et al22 2013 3 (4) 12 100 75 d 25 0
8 Thakar and Chaudhuri23 2013 5 (6) 5.8 100 100 Stent S/O (n ¼ 3) d 0
Total d d 100 (107) 14.0 98.1 89.5 Stent S/O: 13.1%
Stent D: 2.8%
d 4 (4%)
An, Aneurysm; Pat, patients; Stent S/O, stent stenosis or occlusion; Stent D, stent disconnection.
Technical success was deﬁned as successful deployment of the stents to target locations without procedure-related major complication and mortality. Clinical
success was deﬁned as exclusion of the aneurysm from circulation (complete thrombosis of the sac and aneurysm shrinkage/stabilization).
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satisfactory with a clinical success rate of 94.6%. Initial sac
RP and aneurysm morphology might not be associated
with midterm treatment outcome. Further validation of
this technique in large-scale clinical studies is needed to
substantiate these results.
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